The Proteomics Facility provides a comprehensive suite of proteomics services to the Cancer Center membership. The primary emphasis is to provide expert consultation and state-of-the-art technologies operating at maximum performance at affordable costs to Cancer Center members. This is quite challenging because unlike genomics, proteomics technologies are highly varied;there are not consensus optimal approaches for most problems, and instruments, software and analytical strategies continue to evolve rapidly. Therefore, equipment and analytical methods must be continually updated. As a result, most of the instruments in the Facility were purchased within the past grant period, which includes $1.3 million invested in 2008 alone to replace obsolete mass spectrometers with 2 LTQ Orbitrap mass spectrometers and a high sensitivity triple quadropole mass spectrometer. Sensitivity of protein identifications has increased more than 100-fold over the past grant period through a combination of method optimization, acquisition of more sensitive instruments and development of an improved data analysis pipeline. Other methods have been similarly improved and new complementary methods have been implemented. The facility is also beginning to implement quantitative protein profile comparisons on LC-MS/MS based analyses using several complementary approaches, which will be expanded during the next grant period. During the past grant period (2003-present), 19 CC members used the Proteomics Facility and additional members benefited because many projects were collaborative between multiple CC investigators. CC members receive priority in sample analysis, substantial discounts on user fees (35-50% depending upon the service), more extensive consultation, training and assistance, and early access to methods/technologies not yet implemented as routine services. In the current year CCSG support covered 27% of non-equipment operating costs and will cover 23% of operating costs during the first year of the proposed grant. During 2007 44% of facility usage was by peer-reviewed CC members, and over the entire past grant period (2003-present) 61% of facility usage was by peer-reviewed CC members.

Public Health Relevance

Proteomics can only be accomplished as a facility because of the expense of the instrumentation and expertise needed for their operation. Proteomics offer the hope of identifying biomarkers for the early detection of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8932923
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$187,370
Indirect Cost
$84,168
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications